LSDI vs. BPTH, GLMD, PRFX, QLGN, CMND, INM, ATNF, NBSE, SLRX, and NTBL
Should you be buying Lucy Scientific Discovery stock or one of its competitors? The main competitors of Lucy Scientific Discovery include Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), PainReform (PRFX), Qualigen Therapeutics (QLGN), Clearmind Medicine (CMND), InMed Pharmaceuticals (INM), 180 Life Sciences (ATNF), NeuBase Therapeutics (NBSE), Salarius Pharmaceuticals (SLRX), and Notable Labs (NTBL). These companies are all part of the "pharmaceutical preparations" industry.
Lucy Scientific Discovery (NASDAQ:LSDI) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
72.6% of Lucy Scientific Discovery shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 3.1% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Bio-Path has a consensus target price of $40.00, indicating a potential upside of 1,418.03%. Given Bio-Path's higher possible upside, analysts plainly believe Bio-Path is more favorable than Lucy Scientific Discovery.
Lucy Scientific Discovery has higher revenue and earnings than Bio-Path. Lucy Scientific Discovery is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bio-Path had 1 more articles in the media than Lucy Scientific Discovery. MarketBeat recorded 4 mentions for Bio-Path and 3 mentions for Lucy Scientific Discovery. Bio-Path's average media sentiment score of 0.40 beat Lucy Scientific Discovery's score of 0.00 indicating that Bio-Path is being referred to more favorably in the news media.
Bio-Path received 280 more outperform votes than Lucy Scientific Discovery when rated by MarketBeat users. However, 100.00% of users gave Lucy Scientific Discovery an outperform vote while only 55.53% of users gave Bio-Path an outperform vote.
Lucy Scientific Discovery's return on equity of -294.74% beat Bio-Path's return on equity.
Lucy Scientific Discovery has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
Summary
Lucy Scientific Discovery beats Bio-Path on 8 of the 14 factors compared between the two stocks.
Get Lucy Scientific Discovery News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSDI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucy Scientific Discovery Competitors List
Related Companies and Tools
